CEL-SCI (CVM) Hires Vice President of Manufacturing/Facilities and Commercial Operations
VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation , a late-stage oncology company and a developer of vaccines and therapeutics for the treatment of infectious diseases, announced today the appointment of Todd S. Burkhart as Vice President of Manufacturing/Facilities and Commercial Operations for its manufacturing facility. Mr. Burkhart has over 30 years of experience in the manufacture and process development of biologicals, medical devices and other Active Pharmaceutical Ingredients (APIs). During his distinguished career in the Pharmaceutical and Biopharmaceutical Industry and prior to joining CEL-SCI, Mr. Burkhart has been responsible for all aspects of GMP manufacturing and operations, including production, materials controls and facilities maintenance. In addition he has extensive experience in the design of manufacturing facilities meeting FDA GMP requirements. Mr. Burkhart has also been involved in the building and/or running a number of major pharmaceutical facilities at companies such as Cephalon, Human Genome Sciences and Univax Biologics.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global pivotal Phase III clinical trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to treat H1N1 hospitalized patients using its L.E.A.P.S. technology platform. This investigational treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This unique investigational treatment is currently being tested in a clinical study at The Johns Hopkins University Hospital. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.